Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA.
Telesis Bio has raised $74.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Telesis Bio's investors include Novalis LifeSciences, Northpond Ventures, BroadOak Capital Partners, M-185 Corporation.
Telesis Bio is headquartered in San Diego, United States.
Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA.
Telesis Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Telesis Bio — Funding & Investors." VCBacked, May 31, 2023, https://www.vcbacked.co/company/telesis-bio. Accessed September 30, 2026.
VCBacked. (2023). Telesis Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/telesis-bio
{{cite web |title=Telesis Bio — Funding & Investors |url=https://www.vcbacked.co/company/telesis-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated